BAX expression in benign and malignant thyroid tumours: Dysregulation of wild-type p53 is associated with a high BAX and p21 expression in thyroid carcinoma

International Journal of Cancer

Volumn 92, Issue 6, 2001, Pages 805-811

  Hermann, Sandra ^a   Sturm, Isrid ^a,b   Mrozek, Alicja ^a   Klosterhalfen, Bernd ^d   Hauptmann, Steffen ^c   Dörken, Bernd ^a,b   Daniel, Peter T ^a,b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Adenoma; Apoptosis; BAX; Bcl 2; Goitres; Molecular diagnostic; p21; p53; Survival; Thyroid cancer

Indexed keywords

PROTEIN BAX; PROTEIN P21; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GOITER; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID CARCINOMA; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CARCINOMA, PAPILLARY; CYTOPLASM; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENES, P53; GOITER; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035877135     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1284     Document Type: Article

References (51)

1. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Ann Rev Med 1997;48: 267-81.
2. el-Deiry WS. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 1998;227:121-37.
3. Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
4. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
5. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999;13:1899-911.
6. Li P, et al. Cytochrome c and dATP-dependent formation of Apaf-1/ caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91:479-89.
7. Slee EA, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 1999;144:281-92.
8. Knudson CM., Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96-9.
9. Sturm I, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999;17:1364-74.
10. Bargou, et al. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumour growth in SCID mice. J Clin Invest 1996;97:2651-9.
11. Sturm I, et al. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer 2000;87:517-521.
12. Wagener C, et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 1996;67:138-41.
13. Figge J. Epidemiology of thyroid cancer. In: Wartofsky L, editor. Thyroid cancer: a comprehensive guide to clinical management, Totowa, NJ: Humana Press Inc. 1999:77-83.
14. Dobashi Y, et al. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma. Am J Surg Pathol 1993;17: 375-81
15. Donghi RLA., Pilotti S, Michieli P, Della-Porta G, Pierotti MA. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 1993;91:1753-60.
16. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993;91:179-84.
17. Figge J. Molecular pathogenesis of thyroid cancer. In: Wartofsky L. editor. Thyroid cancer: A comprehensive guide to clinical management. Totowa, NJ: Humana Press, Inc. 1999:57-75.
18. Branet F, et al. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland. J clin Endocrinol Metab 1996;81:2726-30.
19. Manetto V, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Arch 1997;430:125-30.
20. Brocker M, de Buhr I, Papageorgiou G, Schatz H, Derwahl M. Expression of apoptosis-related proteins in thyroid tumours and thyroid carcinoma cell lines. Exp Clin Endocrinol Diabetes 1996;104: 20-3.
21. Wang DG, Liu WH, Johnston CF, Sloan JM, Buchanan KD. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumourigenesis. Am J Pathol 1998;152:1407-13.
22. Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest 1996;97:2403-4.
23. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998;16:2583-90.
24. Ho YS, Tseng SC, Chin TY, Hsieh LL, Lin JD. p53 gene mutation in thyroid carcinoma. Cancer Lett 1996;103:57-63.
25. Kitahori Y, Naitoh H, Konishi N, Fukushima M, Ohnishi T, Hiasa Y. G-A mutation of ras genes and infrequent p53 gene mutation in rat transplantable thyroid carcinoma lines from tumours induced in vivo by N-bis(2-hydroxypropyl)nitrosamine. Cancer Lett 1996;100:55-62.
26. Zedenius, J, et al. Alterations of p53 and expression of WAF1/p21 in human thyroid tumours. Thyroid 1996;6:1-9.
27. Krajewski S, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995;55:4471-8.
28. Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc nat Acad Sci (Wash) 1998;95:4997-5002.
29. Zha H, Reed JC. Heterodimerization-independent functions of cell death regulatory proteins Bax and Bcl-2 in yeast and mammalian cells. J Biol Chem 1997;272:31482-8.
30. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Nat Acad Sci (Wash) 1996;93:14559-63.
31. Schlesinger PH, et al. Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. Proc nat Acad Sci (Wash) 1997;94:11357-62.
32. Essmann F, Wieder T, Otto A, Muller EC, Dörken B, Daniel PT. GDP dissociation inhibitor D4-GDI (Rho-GDI 2), but not the homologous rho-GDI 1, is cleaved by caspase-3 during drug-induced apoptosis. Biochem J 2000;346:777-83.
33. Pastorino JG, Chen ST, Tafani M, Snyder JW, Farber JL. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. J Biol Chem 1998;273:7770-5.
34. Prokop A, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2-ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 2000;14:1606-13.
35. Decaudin D, Marzo I, Brenner C, Kroemer G. Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy. Int J Oncol 1998;12:141-52.
36. Liu X, Zou H, Slaughter C, Wang X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997;89:175-84.
37. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
38. Bunz, F, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
39. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-6.
40. Zeng Q, Oakley B., p53 and Bax: putative death factors in taste cell turnover. J Comp Neurol 1999;413:168-80.
41. Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol 1999;155:955-65.
42. Flamini G, et al. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer: an immunohistochemical analysis. Eur J Cancer 1996;32:802-6.
43. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Nat Acad Sci (Wash) 1992;89:7262-6.
44. Stenmark-Askmalm M, et al. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer 1994;2:175-80.
45. Flamini G, et al. Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. J Cancer Res Clin Oncol 1997;123:240-2.
46. Goldenberg JD, et al. Well-differentiated thyroid carcinomas: p53 mutation status and microvessel density. Head Neck 1998;20:152-8.
47. Jossart GH, et al. Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 1996;81:3498-504.
48. Moore D, Ohene-Fianko D, Garcia B, Chakrabarti S. Apoptosis in thyroid neoplasms: relationship with p53 and bcl-2 expression. Histopathology 1998;32:35-42.
49. Reuter A, Dreifus J, Jones M, Nishiyama R, Lennquist S. Overexpression of p53 in tall cell variants of papillary thyroid carcinoma. Surgery 1996;120:1046-50.
50. Zou M, Shi Y, Farid N.R. p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993;77:1054-8.
51. Hogmo A, Munck-Wikland E, Kuylenstierna R, Lindholm J, Auer G. Nuclear DNA content and p53 immunostaining in metachronous preneoplastic lesions and subsequent carcinomas of the oral cavity. Head Neck 1996;18:433-40.